Evogene (NASDAQ:EVGN) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a note issued to investors on Tuesday. The firm set a “sell” rating on the biotechnology company’s stock.

Separately, Alliance Global Partners restated a “buy” rating on shares of Evogene in a report on Friday, March 7th.

Evogene Price Performance

Shares of Evogene stock opened at $1.43 on Tuesday. The stock has a market cap of $7.67 million, a price-to-earnings ratio of -0.32 and a beta of 1.28. Evogene has a twelve month low of $1.20 and a twelve month high of $9.00. The company’s fifty day moving average is $1.51 and its 200 day moving average is $1.93.

Evogene (NASDAQ:EVGN) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.78. Evogene had a negative return on equity of 109.05% and a negative net margin of 314.43%. The firm had revenue of $1.61 million for the quarter, compared to analyst estimates of $3.63 million. During the same quarter in the previous year, the company posted ($1.30) EPS.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC bought a new position in Evogene Ltd. (NASDAQ:EVGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned approximately 0.30% of Evogene as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.